Literature DB >> 9673838

Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.

.   

Abstract

This report describes the first study to evaluate the risks of cardiovascular disease (CVD) associated with the use of oral and injectable progestogen-only and combined injectable contraceptives. Based on combined data from Africa, Asia, Europe, and Latin America collected in the World Health Organization (WHO) Collaborative Study, odds ratios (OR) for CVD combined, strokes, venous thromboembolism (VTE), and acute myocardial infarction (AMI) were calculated. Among 3697 CVD cases (59% stroke, 31% VTE, and 10% AMI), 53, 37, and 13 women, respectively, were current users of oral and injectable progestogen-only and combined injectable contraceptives. Overall, the adjusted OR for all CVD combined compared with nonusers of any type of steroid hormone contraceptive (SHC) associated with current use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives, respectively, were 1.14 (95% CI: 0.79-1.63), 1.02 (0.68-1.54), and 0.95 (0.49-1.86). No significant changes in OR were apparent for strokes, VTE, or AMI in association with any of these types of contraception. However, a small, nonsignificant increase in OR for VTE was apparent in association with oral and injectable progestogen-only contraceptives. Among women with a history of hypertension, OR for stroke, as compared with that for nonusers of any type of SHC with no history of hypertension, rose from 7.2 (6.1-8.5) among nonusers of any type of SHC to 12.4 (4.1-37.6) among current users of all oral progestogens. Although limited by the small number of cases and control subjects using the types of contraceptives under investigation, these data suggest that there is little or no increased risk of stroke, VTE, or AMI associated with the use of oral or injectable progestogen-only or combined injectable contraceptives. However, further investigation into a possible adverse effect on stroke risk of progestogen-only contraceptives used by women with a history of high blood pressure are indicated.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9673838

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  28 in total

Review 1.  Recent developments in hormonal contraception.

Authors:  Eleanor A Drey; Philip D Darney
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

Review 2.  Risks of contraception and pregnancy in heart disease.

Authors:  Sara Thorne; Anne MacGregor; Catherine Nelson-Piercy
Journal:  Heart       Date:  2006-10       Impact factor: 5.994

3.  Acute uterine bleeding unrelated to pregnancy: a Southern California Permanente Medical Group practice guideline.

Authors:  Malcolm G Munro
Journal:  Perm J       Date:  2013

Review 4.  A Systematic Review and Meta-analysis of the Adverse Effects of Levonorgestrel Emergency Oral Contraceptive.

Authors:  Nattawut Leelakanok; Janthima Methaneethorn
Journal:  Clin Drug Investig       Date:  2020-05       Impact factor: 2.859

Review 5.  Choosing the best contraceptive method for the adult with congenital heart disease.

Authors:  Candice K Silversides; Mathew Sermer; Samuel C Siu
Journal:  Curr Cardiol Rep       Date:  2009-07       Impact factor: 2.931

6.  35-year-old woman with recurrent palpitations.

Authors:  Kunal C Kadakia; Paul R Daniels
Journal:  Mayo Clin Proc       Date:  2011-08       Impact factor: 7.616

7.  Contraindications to progestin-only oral contraceptive pills among reproductive-aged women.

Authors:  Kari White; Joseph E Potter; Kristine Hopkins; Leticia Fernández; Jon Amastae; Daniel Grossman
Journal:  Contraception       Date:  2012-02-24       Impact factor: 3.375

Review 8.  Contraception in women over 40 years of age.

Authors:  Rebecca H Allen; Carrie A Cwiak; Andrew M Kaunitz
Journal:  CMAJ       Date:  2013-03-04       Impact factor: 8.262

Review 9.  Contraceptive Considerations for Women with Gastrointestinal Disorders.

Authors:  Aparna Sridhar; Carrie A Cwiak; Andrew M Kaunitz; Rebecca H Allen
Journal:  Dig Dis Sci       Date:  2016-11-24       Impact factor: 3.199

10.  Effect of injectable and oral contraceptives on serum lipids.

Authors:  Abbey B Berenson; Mahbubur Rahman; Gregg Wilkinson
Journal:  Obstet Gynecol       Date:  2009-10       Impact factor: 7.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.